C-POST: adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma

Описание: Danny Rischin, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the Phase III C-POST trial (NCT03969004) of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery and radiation. Cemiplimab significantly prolonged disease-free survival and reduced both local-regional and distant recurrences compared to placebo. Clinical benefit was consistent across PD-L1 subgroups. Safety findings were manageable and in line with expectations. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.